<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p85" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_85{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_85{left:341px;bottom:30px;}
#t3_85{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_85{left:377px;bottom:30px;}
#t5_85{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_85{left:540px;bottom:30px;}
#t7_85{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_85{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_85{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_85{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_85{left:285px;bottom:827px;letter-spacing:-0.37px;word-spacing:0.11px;}
#tc_85{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_85{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_85{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_85{left:1115px;bottom:47px;letter-spacing:0.36px;}
#tg_85{left:1121px;bottom:28px;letter-spacing:0.21px;word-spacing:-0.15px;}
#th_85{left:374px;bottom:778px;letter-spacing:0.35px;word-spacing:-0.19px;}
#ti_85{left:41px;bottom:755px;}
#tj_85{left:53px;bottom:750px;letter-spacing:-0.24px;word-spacing:0.03px;}
#tk_85{left:53px;bottom:735px;letter-spacing:-0.2px;}
#tl_85{left:53px;bottom:720px;letter-spacing:-0.23px;}
#tm_85{left:41px;bottom:709px;}
#tn_85{left:53px;bottom:704px;letter-spacing:-0.21px;}
#to_85{left:53px;bottom:689px;letter-spacing:-0.22px;word-spacing:-0.11px;}
#tp_85{left:53px;bottom:674px;letter-spacing:-0.24px;}
#tq_85{left:41px;bottom:663px;}
#tr_85{left:53px;bottom:659px;letter-spacing:-0.22px;word-spacing:0.01px;}
#ts_85{left:53px;bottom:643px;letter-spacing:-0.22px;}
#tt_85{left:53px;bottom:628px;letter-spacing:-0.24px;}
#tu_85{left:41px;bottom:617px;}
#tv_85{left:53px;bottom:613px;letter-spacing:-0.27px;word-spacing:0.01px;}
#tw_85{left:53px;bottom:597px;letter-spacing:-0.21px;}
#tx_85{left:53px;bottom:582px;letter-spacing:-0.22px;word-spacing:-0.11px;}
#ty_85{left:41px;bottom:571px;}
#tz_85{left:53px;bottom:567px;letter-spacing:-0.22px;word-spacing:0.02px;}
#t10_85{left:53px;bottom:552px;letter-spacing:-0.23px;word-spacing:-0.19px;}
#t11_85{left:41px;bottom:541px;}
#t12_85{left:53px;bottom:536px;letter-spacing:-0.23px;word-spacing:-0.04px;}
#t13_85{left:53px;bottom:521px;letter-spacing:-0.21px;word-spacing:-0.01px;}
#t14_85{left:53px;bottom:506px;letter-spacing:-0.28px;word-spacing:0.04px;}
#t15_85{left:41px;bottom:495px;}
#t16_85{left:53px;bottom:490px;letter-spacing:-0.31px;word-spacing:-0.02px;}
#t17_85{left:53px;bottom:475px;letter-spacing:-0.21px;}
#t18_85{left:53px;bottom:460px;letter-spacing:-0.23px;word-spacing:-0.11px;}
#t19_85{left:41px;bottom:449px;}
#t1a_85{left:53px;bottom:445px;letter-spacing:-0.23px;word-spacing:-0.05px;}
#t1b_85{left:53px;bottom:429px;letter-spacing:-0.22px;}
#t1c_85{left:53px;bottom:414px;letter-spacing:-0.23px;}
#t1d_85{left:41px;bottom:403px;}
#t1e_85{left:53px;bottom:399px;letter-spacing:-0.2px;word-spacing:-0.07px;}
#t1f_85{left:53px;bottom:383px;letter-spacing:-0.22px;word-spacing:-0.08px;}
#t1g_85{left:53px;bottom:368px;letter-spacing:-0.21px;}
#t1h_85{left:37px;bottom:357px;letter-spacing:-0.18px;}
#t1i_85{left:57px;bottom:353px;letter-spacing:-0.3px;word-spacing:-0.07px;}
#t1j_85{left:53px;bottom:338px;letter-spacing:-0.23px;word-spacing:0.02px;}
#t1k_85{left:53px;bottom:322px;letter-spacing:-0.22px;}
#t1l_85{left:53px;bottom:307px;letter-spacing:-0.22px;}
#t1m_85{left:53px;bottom:292px;letter-spacing:-0.24px;}
#t1n_85{left:37px;bottom:281px;letter-spacing:-1.24px;}
#t1o_85{left:56px;bottom:276px;letter-spacing:-0.3px;word-spacing:-0.04px;}
#t1p_85{left:52px;bottom:261px;letter-spacing:-0.22px;}
#t1q_85{left:52px;bottom:246px;letter-spacing:-0.21px;}
#t1r_85{left:52px;bottom:231px;letter-spacing:-0.25px;}
#t1s_85{left:37px;bottom:220px;letter-spacing:-0.18px;}
#t1t_85{left:57px;bottom:215px;letter-spacing:-0.23px;word-spacing:-0.05px;}
#t1u_85{left:53px;bottom:200px;letter-spacing:-0.23px;word-spacing:-0.07px;}
#t1v_85{left:53px;bottom:185px;letter-spacing:-0.23px;word-spacing:-0.04px;}
#t1w_85{left:37px;bottom:174px;letter-spacing:-0.18px;}
#t1x_85{left:57px;bottom:170px;letter-spacing:-0.23px;word-spacing:-0.08px;}
#t1y_85{left:53px;bottom:154px;letter-spacing:-0.22px;}
#t1z_85{left:37px;bottom:144px;letter-spacing:-0.18px;}
#t20_85{left:57px;bottom:139px;letter-spacing:-0.21px;word-spacing:-0.02px;}
#t21_85{left:53px;bottom:124px;letter-spacing:-0.23px;word-spacing:-0.07px;}
#t22_85{left:53px;bottom:108px;letter-spacing:-0.24px;}
#t23_85{left:617px;bottom:755px;letter-spacing:-0.18px;}
#t24_85{left:637px;bottom:750px;letter-spacing:-0.21px;word-spacing:-0.06px;}
#t25_85{left:633px;bottom:735px;letter-spacing:-0.21px;}
#t26_85{left:633px;bottom:719px;letter-spacing:-0.22px;}
#t27_85{left:617px;bottom:709px;letter-spacing:-0.18px;}
#t28_85{left:637px;bottom:704px;letter-spacing:-0.21px;word-spacing:-0.07px;}
#t29_85{left:633px;bottom:689px;letter-spacing:-0.22px;}
#t2a_85{left:633px;bottom:674px;letter-spacing:-0.22px;}
#t2b_85{left:617px;bottom:663px;letter-spacing:-0.18px;}
#t2c_85{left:637px;bottom:658px;letter-spacing:-0.29px;word-spacing:-0.01px;}
#t2d_85{left:633px;bottom:643px;letter-spacing:-0.22px;}
#t2e_85{left:633px;bottom:628px;letter-spacing:-0.26px;word-spacing:0.03px;}
#t2f_85{left:633px;bottom:612px;letter-spacing:-0.23px;word-spacing:-0.2px;}
#t2g_85{left:617px;bottom:602px;letter-spacing:-0.18px;}
#t2h_85{left:637px;bottom:597px;letter-spacing:-0.26px;word-spacing:0.02px;}
#t2i_85{left:633px;bottom:582px;letter-spacing:-0.23px;word-spacing:0.01px;}
#t2j_85{left:633px;bottom:567px;letter-spacing:-0.25px;word-spacing:-0.14px;}
#t2k_85{left:617px;bottom:556px;letter-spacing:-0.18px;}
#t2l_85{left:637px;bottom:551px;letter-spacing:-0.31px;word-spacing:0.04px;}
#t2m_85{left:633px;bottom:536px;letter-spacing:-0.21px;}
#t2n_85{left:633px;bottom:521px;letter-spacing:-0.23px;}
#t2o_85{left:617px;bottom:510px;letter-spacing:-0.18px;}
#t2p_85{left:637px;bottom:506px;letter-spacing:-0.24px;}
#t2q_85{left:633px;bottom:490px;letter-spacing:-0.22px;}
#t2r_85{left:633px;bottom:475px;letter-spacing:-0.21px;}
#t2s_85{left:633px;bottom:460px;letter-spacing:-0.22px;word-spacing:-0.26px;}
#t2t_85{left:617px;bottom:449px;letter-spacing:-0.18px;}
#t2u_85{left:637px;bottom:444px;letter-spacing:-0.24px;word-spacing:0.03px;}
#t2v_85{left:633px;bottom:429px;letter-spacing:-0.23px;}
#t2w_85{left:633px;bottom:414px;letter-spacing:-0.24px;}
#t2x_85{left:617px;bottom:403px;letter-spacing:-0.18px;}
#t2y_85{left:637px;bottom:399px;letter-spacing:-0.2px;}
#t2z_85{left:626px;bottom:383px;letter-spacing:-0.21px;}
#t30_85{left:626px;bottom:368px;letter-spacing:-0.24px;}
#t31_85{left:617px;bottom:357px;letter-spacing:-0.18px;}
#t32_85{left:637px;bottom:353px;letter-spacing:-0.2px;}
#t33_85{left:633px;bottom:337px;letter-spacing:-0.21px;}
#t34_85{left:633px;bottom:322px;letter-spacing:-0.24px;}
#t35_85{left:617px;bottom:311px;letter-spacing:-0.18px;}
#t36_85{left:637px;bottom:307px;letter-spacing:-0.26px;word-spacing:0.04px;}
#t37_85{left:637px;bottom:292px;letter-spacing:-0.21px;}
#t38_85{left:637px;bottom:276px;letter-spacing:-0.24px;}
#t39_85{left:617px;bottom:266px;letter-spacing:-0.18px;}
#t3a_85{left:637px;bottom:261px;letter-spacing:-0.21px;word-spacing:-0.12px;}
#t3b_85{left:633px;bottom:246px;letter-spacing:-0.22px;}
#t3c_85{left:633px;bottom:230px;letter-spacing:-0.21px;}
#t3d_85{left:633px;bottom:215px;letter-spacing:-0.27px;word-spacing:0.02px;}
#t3e_85{left:617px;bottom:204px;letter-spacing:-0.18px;}
#t3f_85{left:637px;bottom:200px;letter-spacing:-0.21px;}
#t3g_85{left:633px;bottom:185px;letter-spacing:-0.23px;}
#t3h_85{left:633px;bottom:169px;letter-spacing:-0.3px;word-spacing:0.06px;}
#t3i_85{left:617px;bottom:159px;letter-spacing:-0.18px;}
#t3j_85{left:637px;bottom:154px;letter-spacing:-0.25px;word-spacing:0.02px;}
#t3k_85{left:626px;bottom:139px;letter-spacing:-0.21px;}
#t3l_85{left:626px;bottom:123px;letter-spacing:-0.22px;}
#t3m_85{left:626px;bottom:108px;letter-spacing:-0.24px;}
#t3n_85{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_85{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_85{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_85{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_85{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_85{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_85{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_85{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s7_85{font-size:15px;font-family:ArialMT_k0;color:#000;}
.s8_85{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts85" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg85Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg85" style="-webkit-user-select: none;"><object width="1210" height="935" data="85/85.svg" type="image/svg+xml" id="pdf85" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_85" class="t s0_85">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_85" class="t s1_85">® </span>
<span id="t3_85" class="t s0_85">(NCCN </span>
<span id="t4_85" class="t s1_85">® </span>
<span id="t5_85" class="t s0_85">), All rights reserved. NCCN Guidelines </span>
<span id="t6_85" class="t s1_85">® </span>
<span id="t7_85" class="t s0_85">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_85" class="t s2_85">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_85" class="t s2_85">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_85" class="t s3_85">NCCN Guidelines Version 4.2024 </span>
<span id="tb_85" class="t s3_85">Salivary Gland Tumors </span>
<span id="tc_85" class="t s4_85">NCCN Guidelines Index </span>
<span id="td_85" class="t s4_85">Table of Contents </span>
<span id="te_85" class="t s4_85">Discussion </span>
<span id="tf_85" class="t s5_85">SALI-B </span>
<span id="tg_85" class="t s5_85">2 OF 2 </span>
<span id="th_85" class="t s5_85">SYSTEMIC THERAPY FOR SALIVARY GLAND TUMORS </span>
<span id="ti_85" class="t s6_85">1 </span>
<span id="tj_85" class="t s7_85">Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing </span>
<span id="tk_85" class="t s6_85">vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland </span>
<span id="tl_85" class="t s6_85">malignancies. Cancer 2001;91:541-547. </span>
<span id="tm_85" class="t s6_85">2 </span>
<span id="tn_85" class="t s6_85">Licitra L, Cavina R, Grandi C, Pet al. Cisplatin, doxorubicin and cyclophosphamide </span>
<span id="to_85" class="t s6_85">in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol </span>
<span id="tp_85" class="t s6_85">1996;7:640-642. </span>
<span id="tq_85" class="t s6_85">3 </span>
<span id="tr_85" class="t s6_85">Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies </span>
<span id="ts_85" class="t s6_85">(E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck </span>
<span id="tt_85" class="t s6_85">2006;28:197-204. </span>
<span id="tu_85" class="t s6_85">4 </span>
<span id="tv_85" class="t s6_85">Nakano K, Sato Y, Sasaki T, et al. Combination chemotherapy of carboplatin and </span>
<span id="tw_85" class="t s6_85">paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in </span>
<span id="tx_85" class="t s6_85">responses by different pathological diagnoses. Acta Otolaryngol. 2016;136:948-951. </span>
<span id="ty_85" class="t s6_85">5 </span>
<span id="tz_85" class="t s6_85">Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary </span>
<span id="t10_85" class="t s6_85">gland malignancies. Anticancer Res 2000;20:3781-3783. </span>
<span id="t11_85" class="t s6_85">6 </span>
<span id="t12_85" class="t s6_85">Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine </span>
<span id="t13_85" class="t s6_85">in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials </span>
<span id="t14_85" class="t s6_85">Group. Cancer 2010;116:362-368. </span>
<span id="t15_85" class="t s6_85">7 </span>
<span id="t16_85" class="t s6_85">Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined </span>
<span id="t17_85" class="t s6_85">androgen blockade in patients with androgen receptor-positive metastatic or locally </span>
<span id="t18_85" class="t s6_85">advanced unresectable salivary gland carcinoma. Ann Oncol 2018;29:979-984. </span>
<span id="t19_85" class="t s6_85">8 </span>
<span id="t1a_85" class="t s6_85">Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen </span>
<span id="t1b_85" class="t s6_85">receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 </span>
<span id="t1c_85" class="t s6_85">patients in the Netherlands. Head Neck 2018;40:605-613. </span>
<span id="t1d_85" class="t s6_85">9 </span>
<span id="t1e_85" class="t s6_85">Locati L, Cavalieri S, Bergamini C, et al. Abiraterone acetate in patients with </span>
<span id="t1f_85" class="t s6_85">castration-resistant, androgen receptor-expressing salivary gland cancer: A phase II </span>
<span id="t1g_85" class="t s6_85">trial. J Clin Oncol 2021;39:4061-4068. </span>
<span id="t1h_85" class="t s6_85">10 </span>
<span id="t1i_85" class="t s7_85">Honma Y, Monden N, Yamazaki K, et al. Yatagarasu: A single-arm, open-label, </span>
<span id="t1j_85" class="t s6_85">phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (Pts) with far </span>
<span id="t1k_85" class="t s6_85">locally advanced or recurrent/metastatic (FLa/RM) and androgen receptor (AR)- </span>
<span id="t1l_85" class="t s6_85">expressing salivary gland carcinoma (SGC) [abstract]. J Clin Oncol 2022;40:6079- </span>
<span id="t1m_85" class="t s6_85">6079. </span>
<span id="t1n_85" class="t s6_85">11 </span>
<span id="t1o_85" class="t s6_85">Patel M, Fujioka N, Pease DF, et al. BTCRC-HN17-111, A phase 2 trial of ADT </span>
<span id="t1p_85" class="t s7_85">(Goserelin) in combination with pembrolizumab for patients with advanced </span>
<span id="t1q_85" class="t s6_85">salivary gland tumors expressing androgen receptor (Ar) [abstract]. J Clin Oncol </span>
<span id="t1r_85" class="t s6_85">2022;40:e18091-e18091. </span>
<span id="t1s_85" class="t s6_85">12 </span>
<span id="t1t_85" class="t s6_85">Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen </span>
<span id="t1u_85" class="t s6_85">receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 </span>
<span id="t1v_85" class="t s6_85">patients in The Netherlands. Head Neck 2018;40:605-613 </span>
<span id="t1w_85" class="t s6_85">13 </span>
<span id="t1x_85" class="t s6_85">Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion- </span>
<span id="t1y_85" class="t s6_85">positive cancers in adults and children. N Engl J Med 2018;378:731-739. </span>
<span id="t1z_85" class="t s6_85">14 </span>
<span id="t20_85" class="t s6_85">Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: </span>
<span id="t21_85" class="t s6_85">a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019;30:325- </span>
<span id="t22_85" class="t s6_85">331. </span>
<span id="t23_85" class="t s6_85">15 </span>
<span id="t24_85" class="t s7_85">Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or </span>
<span id="t25_85" class="t s6_85">metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase </span>
<span id="t26_85" class="t s6_85">1-2 trials. Lancet Oncol 2020;21:271-282. </span>
<span id="t27_85" class="t s6_85">16 </span>
<span id="t28_85" class="t s6_85">Thorpe LM, Schrock AB, Erlich RL, et al. Significant and durable clinical benefit </span>
<span id="t29_85" class="t s7_85">from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a </span>
<span id="t2a_85" class="t s6_85">review of the literature. Head Neck 2017;39:E40-E44. </span>
<span id="t2b_85" class="t s6_85">17 </span>
<span id="t2c_85" class="t s7_85">Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine (T-DM1) in </span>
<span id="t2d_85" class="t s6_85">patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal </span>
<span id="t2e_85" class="t s6_85">junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) </span>
<span id="t2f_85" class="t s6_85">subprotocol Q. Ann Oncol 2019;30:1821-1830. </span>
<span id="t2g_85" class="t s6_85">18 </span>
<span id="t2h_85" class="t s7_85">Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary </span>
<span id="t2i_85" class="t s6_85">gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa </span>
<span id="t2j_85" class="t s6_85">multiple basket study. Ann Oncol 2020;31:412-421. </span>
<span id="t2k_85" class="t s6_85">19 </span>
<span id="t2l_85" class="t s7_85">Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel </span>
<span id="t2m_85" class="t s6_85">in patients with human epidermal growth factor receptor 2-positive salivary duct </span>
<span id="t2n_85" class="t s6_85">carcinoma. J Clin Oncol 2019;37:125-134. </span>
<span id="t2o_85" class="t s6_85">20 </span>
<span id="t2p_85" class="t s7_85">Bando H, Kinoshita I, Modi S, et al. Trastuzumab deruxtecan (T-DXd) in patients </span>
<span id="t2q_85" class="t s6_85">with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct </span>
<span id="t2r_85" class="t s6_85">carcinoma: Subgroup analysis of two phase 1 studies [abstract]. J Clin Oncol </span>
<span id="t2s_85" class="t s6_85">2021;39 (no.15_suppl): Abstract 6079. </span>
<span id="t2t_85" class="t s6_85">21 </span>
<span id="t2u_85" class="t s6_85">Thomson DJ, Silva P, Denton K, et al. Phase II trial of sorafenib in advanced </span>
<span id="t2v_85" class="t s6_85">salivary adenoid cystic carcinoma of the head and neck. Head Neck 2015;37:182- </span>
<span id="t2w_85" class="t s6_85">187. </span>
<span id="t2x_85" class="t s6_85">22 </span>
<span id="t2y_85" class="t s6_85">Locati LD, Cavalieri S, Bergamini C, et al. Phase II trial with axitinib in recurrent </span>
<span id="t2z_85" class="t s6_85">and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head Neck </span>
<span id="t30_85" class="t s6_85">2019;41:3670-3676. </span>
<span id="t31_85" class="t s6_85">23 </span>
<span id="t32_85" class="t s6_85">Ferrarotto R, Sousa LG, Feng L, et al. Phase II clinical trial of axitinib and avelumab </span>
<span id="t33_85" class="t s6_85">in patients with recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol </span>
<span id="t34_85" class="t s6_85">2023;41:2843-2851. </span>
<span id="t35_85" class="t s6_85">24 </span>
<span id="t36_85" class="t s6_85">Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of lenvatinib in patients </span>
<span id="t37_85" class="t s6_85">with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol </span>
<span id="t38_85" class="t s6_85">2019;37:1529-1537. </span>
<span id="t39_85" class="t s6_85">25 </span>
<span id="t3a_85" class="t s7_85">Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with </span>
<span id="t3b_85" class="t s7_85">outcomes in patients with advanced solid tumours treated with pembrolizumab: </span>
<span id="t3c_85" class="t s6_85">prospective biomarker analysis of the multicohort, open-label, phase 2 </span>
<span id="t3d_85" class="t s6_85">KEYNOTE-158 study. Lancet Oncol 2020;21:1353-1365. </span>
<span id="t3e_85" class="t s6_85">26 </span>
<span id="t3f_85" class="t s6_85">Lin VTG, Nabell LM, Spencer SA, et al. First-line treatment of widely metastatic </span>
<span id="t3g_85" class="t s6_85">BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition. J </span>
<span id="t3h_85" class="t s6_85">Natl Compr Canc Netw 2018;16:1166-1170. </span>
<span id="t3i_85" class="t s6_85">27 </span>
<span id="t3j_85" class="t s6_85">Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of </span>
<span id="t3k_85" class="t s6_85">selpercatinib in patients with RET fusion-positive solid tumours other than lung or </span>
<span id="t3l_85" class="t s6_85">thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol </span>
<span id="t3m_85" class="t s6_85">2022;23:1261-1273. </span>
<span id="t3n_85" class="t s8_85">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
